bioMérieux's Stock Slides Toward Its Technical Support at €89.10 After a 21% Drop Over Three Months

Market Context and Recent Performance

bioMérieux's stock fell by 3.29% this Thursday, closing at €89.60, amidst a generally negative atmosphere in the Parisian market. The CAC 40 ended the day down 0.51% at 8,221.46 points, while the SBF 120 dropped 0.55% to 6,222.88 points at the close. The stock's weekly performance was equally unfavorable, showing a decline of 3.34% over the last seven days. Over the year, the company’s market capitalization has shrunk by nearly 22%, indicating a prolonged erosion in the valuation of the Lyon-based group.

In the healthcare sector, dynamics were mixed: Sanofi fell by 0.69%, while UCB gained 0.75%. The announcement of the first quarter 2026 revenue, scheduled for April 23, will be a crucial moment to assess the group's commercial momentum and the trajectory of its various product lines.

Technical Perspective

From a technical standpoint, bioMérieux's stock is priced at €89.60, just cents away from the identified support level at €89.10. A downward breach of this level could pave the way for a new phase of decline. The stock is trading in the lower part of the Bollinger Bands, with the lower boundary at €88.50: this position, only 14% above this boundary, signals a potential oversold zone, often interpreted as a short-term bearish excess.

The gap with the moving averages confirms this deterioration in trend. The stock is trading significantly below its 50-day moving average (€94.73) and even more so below its 200-day moving average (€109.33), reflecting a degraded positioning in the medium and long term. The RSI, at 47, remains in a neutral zone, without extreme signals from a buying or selling dynamics perspective. The nearest resistance lies at €101.00, a level that would require a rebound of more than 12% to be reached.